JP2025063176A5 - - Google Patents
Info
- Publication number
- JP2025063176A5 JP2025063176A5 JP2025004802A JP2025004802A JP2025063176A5 JP 2025063176 A5 JP2025063176 A5 JP 2025063176A5 JP 2025004802 A JP2025004802 A JP 2025004802A JP 2025004802 A JP2025004802 A JP 2025004802A JP 2025063176 A5 JP2025063176 A5 JP 2025063176A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- acceptable salt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893604P | 2019-08-29 | 2019-08-29 | |
| US62/893,604 | 2019-08-29 | ||
| US202063052840P | 2020-07-16 | 2020-07-16 | |
| US63/052,840 | 2020-07-16 | ||
| US202063058188P | 2020-07-29 | 2020-07-29 | |
| US63/058,188 | 2020-07-29 | ||
| PCT/US2020/048194 WO2021041671A1 (en) | 2019-08-29 | 2020-08-27 | Kras g12d inhibitors |
| JP2022513171A JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513171A Division JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025063176A JP2025063176A (ja) | 2025-04-15 |
| JP2025063176A5 true JP2025063176A5 (enExample) | 2025-10-08 |
Family
ID=74683570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513171A Active JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| JP2025004802A Pending JP2025063176A (ja) | 2019-08-29 | 2025-01-14 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513171A Active JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11453683B1 (enExample) |
| EP (1) | EP4021444A4 (enExample) |
| JP (2) | JP7622043B2 (enExample) |
| KR (1) | KR20220071193A (enExample) |
| CN (1) | CN114615981B (enExample) |
| AU (1) | AU2020337938B2 (enExample) |
| BR (1) | BR112022003543A2 (enExample) |
| CA (1) | CA3148745A1 (enExample) |
| CL (1) | CL2022000447A1 (enExample) |
| CO (1) | CO2022003782A2 (enExample) |
| IL (1) | IL290845A (enExample) |
| MX (1) | MX2022002465A (enExample) |
| PH (1) | PH12022550469A1 (enExample) |
| TW (2) | TW202523663A (enExample) |
| WO (1) | WO2021041671A1 (enExample) |
| ZA (1) | ZA202202362B (enExample) |
Families Citing this family (228)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| PT3849537T (pt) | 2018-09-10 | 2025-01-22 | Mirati Therapeutics Inc | Terapêuticas de combinação |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| CA3112129A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| KR20220071193A (ko) * | 2019-08-29 | 2022-05-31 | 미라티 테라퓨틱스, 인크. | Kras g12d 억제제 |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN115135315B (zh) | 2019-12-20 | 2024-11-26 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| US20230279025A1 (en) * | 2020-07-16 | 2023-09-07 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022031678A1 (en) | 2020-08-04 | 2022-02-10 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US20230357233A1 (en) * | 2020-08-26 | 2023-11-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| EP4203952A4 (en) | 2020-08-28 | 2024-12-11 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| MX2023002942A (es) | 2020-09-11 | 2023-05-22 | Mirati Therapeutics Inc | Formas cristalinas de un inhibidor de kras g12c. |
| US20230081426A1 (en) * | 2020-09-18 | 2023-03-16 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| EP4223761A4 (en) * | 2020-09-30 | 2025-03-12 | Shanghai Pharmaceuticals Holding Co., Ltd. | QUINAZOLINE COMPOUND AND ITS APPLICATION |
| US20240034733A1 (en) * | 2020-11-03 | 2024-02-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CA3198885A1 (en) | 2020-12-15 | 2022-06-23 | Xiaolun Wang | Azaquinazoline pan-kras inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
| WO2022135470A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| WO2022135390A1 (zh) * | 2020-12-25 | 2022-06-30 | 四川海思科制药有限公司 | 己酮糖激酶抑制剂及其用途 |
| CN116848112A (zh) * | 2021-02-09 | 2023-10-03 | 南京明德新药研发有限公司 | 吡啶[4，3-d]嘧啶类化合物 |
| CN116848120A (zh) | 2021-02-15 | 2023-10-03 | 安斯泰来制药株式会社 | 用于诱导g12d突变kras蛋白分解的喹唑啉化合物 |
| CA3211110A1 (en) | 2021-02-15 | 2022-08-18 | Astellas Pharma Inc. | 4-aminoquinazoline compound |
| WO2022184178A1 (en) * | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| WO2022192332A1 (en) * | 2021-03-10 | 2022-09-15 | Beta Pharma, Inc. | Pyridopyrimidine derivatives as kras inhibitors |
| CN115260214A (zh) * | 2021-04-29 | 2022-11-01 | 药雅科技(上海)有限公司 | 稠环类krasg12d突变蛋白抑制剂的制备及其应用 |
| WO2022194066A1 (zh) * | 2021-03-15 | 2022-09-22 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN115304603B (zh) * | 2021-05-07 | 2024-04-09 | 药雅科技(上海)有限公司 | 喹唑啉类抑制剂的制备及其应用 |
| CN115490689B (zh) * | 2021-06-17 | 2024-04-09 | 药雅科技(上海)有限公司 | 不可逆krasg12c抑制剂的制备及其应用 |
| CN115160309B (zh) * | 2021-04-07 | 2024-04-09 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白杂环类抑制剂的制备及其应用 |
| CN115073451A (zh) * | 2021-03-15 | 2022-09-20 | 药雅科技(上海)有限公司 | Krasg12d突变蛋白抑制剂的制备及其应用 |
| TWI810803B (zh) * | 2021-03-15 | 2023-08-01 | 大陸商藥雅科技（上海）有限公司 | 突變蛋白抑制劑的製備及其應用 |
| CN115073450A (zh) * | 2021-03-15 | 2022-09-20 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白抑制剂的制备及其应用 |
| WO2022194191A1 (en) * | 2021-03-16 | 2022-09-22 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12d |
| EP4310091A4 (en) * | 2021-03-17 | 2025-04-16 | Genfleet Therapeutics (Shanghai) Inc. | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN115109078A (zh) * | 2021-03-22 | 2022-09-27 | 苏州泽璟生物制药股份有限公司 | 嘧啶并吡啶类抑制剂及其制备方法和应用 |
| CN115124524A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 三环类衍生物及其制备方法和用途 |
| CN116157400B (zh) * | 2021-03-30 | 2024-10-22 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| CN117659051A (zh) * | 2021-03-30 | 2024-03-08 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| CN115197245A (zh) * | 2021-04-09 | 2022-10-18 | 上海拓界生物医药科技有限公司 | 一种Kras抑制剂及其制备方法 |
| WO2022217042A1 (en) * | 2021-04-09 | 2022-10-13 | Ikena Oncology, Inc. | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions |
| WO2022214102A1 (zh) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| US20240239788A1 (en) * | 2021-04-16 | 2024-07-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12d mutant |
| WO2022227987A1 (zh) * | 2021-04-28 | 2022-11-03 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| MX2023012725A (es) * | 2021-04-29 | 2024-09-23 | Amgen Inc | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. |
| WO2022228543A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 桥环类化合物、其制备方法及其在医药上的应用 |
| EP4332105A4 (en) * | 2021-04-30 | 2025-05-28 | Genfleet Therapeutics (Shanghai) Inc. | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE |
| CN115260158A (zh) * | 2021-04-30 | 2022-11-01 | 上海医药集团股份有限公司 | 一种靶向蛋白调节剂的化合物及其应用 |
| CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2022236578A1 (en) * | 2021-05-10 | 2022-11-17 | Nikang Therapeutics, Inc. | Exocyclic amino quinazoline derivatives as kras inhibitors |
| UY39779A (es) * | 2021-05-21 | 2023-01-31 | Blossomhill Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| CA3217694A1 (en) | 2021-05-24 | 2022-12-01 | Zusheng XU | Nitrogen-containing heterocyclic compound, method for preparing same and use of same |
| WO2022247757A1 (zh) * | 2021-05-26 | 2022-12-01 | 南京明德新药研发有限公司 | 氟取代的嘧啶并吡啶类化合物及其应用 |
| MX2023014138A (es) | 2021-05-28 | 2024-02-13 | Redx Pharma Plc | Compuestos. |
| EP4352053A1 (en) | 2021-06-09 | 2024-04-17 | Eli Lilly and Company | Substituted fused azines as kras g12d inhibitors |
| AU2022288151A1 (en) | 2021-06-10 | 2024-01-18 | Redx Pharma Plc | Quinazoline derivatives useful as ras inhibitiors |
| WO2022262686A1 (en) * | 2021-06-13 | 2022-12-22 | Jingrui Biopharma Co., Ltd. | Kras g12d inhibitors |
| WO2022266069A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Tricyclic kras g12d inhibitors |
| WO2022266167A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Amide and urea-containing tricyclic kras inhibitors |
| TW202317580A (zh) * | 2021-06-18 | 2023-05-01 | 大陸商南京燧坤智能科技有限公司 | 用作ｋｒａｓ ｇ１２ｄ抑制劑的氘代化合物 |
| WO2022268051A1 (zh) | 2021-06-21 | 2022-12-29 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2022271823A1 (en) * | 2021-06-23 | 2022-12-29 | Newave Pharmaceutical Inc. | Mutant kras modulators and uses thereof |
| JP2024524524A (ja) | 2021-06-30 | 2024-07-05 | 上海艾力斯医薬科技股▲ふん▼有限公司 | 窒素含有複素環化合物、その製造方法、中間体及び使用 |
| US20240327425A1 (en) * | 2021-07-02 | 2024-10-03 | Shanghai De Novo Pharmatech Co., Ltd. | Kras g12d inhibitor and use thereof |
| CN117460737A (zh) * | 2021-07-05 | 2024-01-26 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
| CN117751116A (zh) * | 2021-07-07 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为KRas G12D抑制剂的稠环化合物 |
| WO2023284730A1 (en) * | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| WO2023283933A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Biotech Co., Ltd. | Compounds useful as kras g12d inhibitors |
| WO2023284537A1 (en) * | 2021-07-16 | 2023-01-19 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| WO2023284881A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| TW202321261A (zh) * | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | 選擇性ｋｒａｓ抑制劑 |
| JP2024532735A (ja) * | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| WO2023018812A1 (en) * | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2023020347A1 (zh) * | 2021-08-16 | 2023-02-23 | 华润医药研究院（深圳）有限公司 | 嘧啶并吡啶类化合物及其制备方法和医药用途 |
| US20250019377A1 (en) * | 2021-08-18 | 2025-01-16 | Jacobio Pharmaceuticals Co., Ltd | 1, 4-oxazepane derivatives and uses thereof |
| WO2023020521A1 (en) * | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | Pyridine fused pyrimidine derivatives and use thereof |
| WO2023020523A1 (en) * | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | Bicyclic derivatives and use thereof |
| CN116323625A (zh) * | 2021-08-25 | 2023-06-23 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| US20250276982A1 (en) * | 2021-09-03 | 2025-09-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| CN116284055B (zh) * | 2021-09-10 | 2025-09-23 | 润佳（苏州）医药科技有限公司 | 一种kras抑制剂及其用途 |
| CN115785124B (zh) * | 2021-09-10 | 2024-11-08 | 润佳（苏州）医药科技有限公司 | Kras g12d抑制剂及其用途 |
| US20240409558A1 (en) | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| CN116143805B (zh) * | 2021-09-17 | 2025-10-17 | 上海凌达生物医药有限公司 | 一类含氮杂环联芳基类化合物、制备方法和用途 |
| WO2023051586A1 (zh) * | 2021-09-29 | 2023-04-06 | 先声再明医药有限公司 | Kras g12d抑制剂化合物及其制备方法和应用 |
| IL311834A (en) * | 2021-10-05 | 2024-05-01 | Mirati Therapeutics Inc | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods |
| US20240408099A1 (en) * | 2021-10-05 | 2024-12-12 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS |
| JP2024537137A (ja) * | 2021-10-05 | 2024-10-10 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 |
| CN118401254A (zh) * | 2021-10-05 | 2024-07-26 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂与shp-2抑制剂的组合疗法 |
| AU2022361380A1 (en) * | 2021-10-05 | 2024-04-11 | Mirati Therapeutics, Inc. | Combination therapies of kras g12d inhibitors with sos1 inhibitors |
| WO2023056951A1 (zh) * | 2021-10-08 | 2023-04-13 | 杭州德睿智药科技有限公司 | 芳基取代并杂环化合物 |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| WO2023061463A1 (zh) * | 2021-10-15 | 2023-04-20 | 广东东阳光药业有限公司 | 新的嘧啶并吡啶化合物、其药物组合物及其用途 |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| WO2023077441A1 (en) * | 2021-11-05 | 2023-05-11 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| CN118302162A (zh) * | 2021-11-24 | 2024-07-05 | 默沙东有限责任公司 | Kras突变蛋白的小分子抑制剂 |
| EP4405337A4 (en) * | 2021-11-30 | 2025-11-26 | Beta Pharma Inc | Fused pyrimidine derivatives as kras oncoprotein inhibitors |
| CN117940436A (zh) * | 2021-12-02 | 2024-04-26 | 上海和誉生物医药科技有限公司 | 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用 |
| CN116217591A (zh) * | 2021-12-02 | 2023-06-06 | 思路迪生物医药(上海)有限公司 | 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物 |
| CN118055932A (zh) * | 2021-12-02 | 2024-05-17 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其制备和在药学上的应用 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN116253748A (zh) * | 2021-12-09 | 2023-06-13 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| EP4452974A4 (en) * | 2021-12-21 | 2025-11-19 | Bridgene Biosciences Inc | RAS ONCOPROTEIN INHIBITORS |
| WO2023119677A1 (en) * | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
| CN116332959A (zh) * | 2021-12-24 | 2023-06-27 | 苏州泽璟生物制药股份有限公司 | Krasg12d蛋白水解调节剂及其制备方法和应用 |
| CN118434740A (zh) * | 2021-12-31 | 2024-08-02 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2023134465A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海艾力斯医药科技股份有限公司 | 一种含氮杂环化合物、其制备方法、中间体及应用 |
| WO2023137223A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| TWI841200B (zh) * | 2022-01-21 | 2024-05-01 | 大陸商上海湃隆生物科技有限公司 | 雜環類化合物、藥物組成物及其應用 |
| CR20240347A (es) | 2022-01-21 | 2025-02-17 | Usynova Pharmaceuticals Ltd | Compuestos de benzopirimidina y uso de estos |
| WO2023138524A1 (zh) * | 2022-01-24 | 2023-07-27 | 贝达药业股份有限公司 | Kras g12d降解剂及其在医药上的应用 |
| CN118679170A (zh) * | 2022-01-28 | 2024-09-20 | 上海艾力斯医药科技股份有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
| WO2023143623A1 (zh) | 2022-01-30 | 2023-08-03 | 上海医药集团股份有限公司 | 一种喹啉类化合物及其应用 |
| JP7713603B2 (ja) | 2022-02-09 | 2025-07-25 | クアンタ セラピューティクス， インコーポレイテッド | Ｋｒａｓモジュレーターおよびその使用 |
| US20250154170A1 (en) | 2022-02-10 | 2025-05-15 | Bayer Aktiengesellschaft | Fused pyrimidines as kras inhibitors |
| WO2023151621A1 (zh) * | 2022-02-11 | 2023-08-17 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| WO2023173014A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors and their use |
| CN116891514A (zh) * | 2022-04-06 | 2023-10-17 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| EP4489738A1 (en) | 2022-03-11 | 2025-01-15 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| TW202346270A (zh) | 2022-03-11 | 2023-12-01 | 日商安斯泰來製藥股份有限公司 | 用於誘發g12d突變kras蛋白分解之雜環化合物 |
| EP4497751A1 (en) * | 2022-03-22 | 2025-01-29 | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Substituted bridged ring inhibitor, preparation method therefor and application thereof |
| KR102847563B1 (ko) | 2022-03-25 | 2025-08-20 | 일라이 릴리 앤드 캄파니 | Kras 억제제 |
| KR20240167633A (ko) | 2022-03-31 | 2024-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료용 약학 조성물 |
| AU2023254280A1 (en) | 2022-04-11 | 2024-09-12 | Chengdu Hyperway Pharmaceuticals Co., Ltd. | Fused ring compound, pharmaceutical composition containing same, and use of fused ring compound |
| CN119365459A (zh) * | 2022-04-11 | 2025-01-24 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的多环化合物 |
| WO2023198191A1 (zh) * | 2022-04-15 | 2023-10-19 | 杭州多域生物技术有限公司 | 一种六元并六元化合物、制备方法、药物组合物和应用 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2023212549A1 (en) * | 2022-04-26 | 2023-11-02 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20250313577A1 (en) * | 2022-04-26 | 2025-10-09 | Erasca, Inc | Tricyclic pyridones and pyrimidones |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| JP2025515139A (ja) | 2022-05-06 | 2025-05-13 | パック セラピューティクス インコーポレイテッド | Ｋｒａｓ ｇ１２ｄタンパク質分解標的化キメラ |
| CN119768408A (zh) * | 2022-05-13 | 2025-04-04 | 珃诺生物医药科技(杭州)有限公司 | Kras（g12d）抑制剂 |
| KR20250013185A (ko) | 2022-05-19 | 2025-01-31 | 제넨테크, 인크. | 아자-테트라시클릭 옥사제핀 화합물 및 이의 용도 |
| CA3257281A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics Inc | PYRIMIDINE-BASED MODULATORS AND THEIR USES |
| CN114907387B (zh) * | 2022-05-26 | 2023-11-10 | 中山大学 | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 |
| JP2025519584A (ja) | 2022-06-10 | 2025-06-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤としてのピリド［４，３－ｄ］ピリミジン誘導体 |
| KR20250024077A (ko) * | 2022-06-15 | 2025-02-18 | 미라티 테라퓨틱스, 인크. | Pan-kras 억제제의 전구약물 |
| WO2023246903A1 (zh) * | 2022-06-24 | 2023-12-28 | 暨南大学 | 含硒杂环类化合物及其药用组合物和应用 |
| CN119095844A (zh) * | 2022-06-29 | 2024-12-06 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
| CN117327102A (zh) * | 2022-06-30 | 2024-01-02 | 北京华森英诺生物科技有限公司 | Kras抑制剂、其制备方法及应用 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| CA3261000A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS |
| EP4551574A1 (en) * | 2022-07-07 | 2025-05-14 | BeiGene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024008178A1 (zh) * | 2022-07-08 | 2024-01-11 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| AR129976A1 (es) | 2022-07-21 | 2024-10-16 | Astellas Pharma Inc | Compuestos heterocíclicos que actúan sobre la proteína kras mutante g12d |
| JP2025524846A (ja) | 2022-07-27 | 2025-08-01 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合環系化合物、その調製方法及びその医薬的使用 |
| EP4563151A4 (en) | 2022-07-29 | 2025-11-05 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PHARMACEUTICAL COMPOSITION COMPRISING A KRAS G12D INHIBITOR |
| EP4567033A1 (en) | 2022-08-05 | 2025-06-11 | Astellas Pharma Inc. | Heterocyclic compound for inducing degradation of mutant kras protein |
| WO2024031088A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN119585278A (zh) * | 2022-08-05 | 2025-03-07 | 杭州中美华东制药有限公司 | 具有KRas G12D抑制作用的化合物 |
| CN119677726A (zh) | 2022-08-11 | 2025-03-21 | 百时美施贵宝公司 | Kras抑制剂 |
| WO2024034123A1 (ja) * | 2022-08-12 | 2024-02-15 | アステラス製薬株式会社 | 複素環化合物を含む医薬組成物 |
| WO2024040109A2 (en) * | 2022-08-16 | 2024-02-22 | Bristol-Myers Squibb Company | Kras inhibitors |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| CN120018863A (zh) * | 2022-08-24 | 2025-05-16 | 珃诺生物医药科技(杭州)有限公司 | 用于调节kras(g12d)的方法和组合物 |
| WO2024045066A1 (en) * | 2022-08-31 | 2024-03-07 | Nikang Therapeutics, Inc. | Alkylidene carbamate as kras inhibitors |
| WO2024054926A1 (en) * | 2022-09-07 | 2024-03-14 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
| WO2024054625A2 (en) * | 2022-09-08 | 2024-03-14 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway |
| TW202426463A (zh) * | 2022-09-09 | 2024-07-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含嘧啶多環類生物抑制劑、其製備方法和應用 |
| CN119894892A (zh) * | 2022-09-16 | 2025-04-25 | 正大天晴药业集团股份有限公司 | 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物 |
| WO2024061333A1 (zh) * | 2022-09-21 | 2024-03-28 | 甘李药业股份有限公司 | 一种kras突变蛋白抑制剂、及其制备方法和应用 |
| KR20250075709A (ko) | 2022-09-30 | 2025-05-28 | 트라스베다 리미티드 | 항-kras 돌연변이 종양 활성을 갖는 화합물 |
| JP2025536369A (ja) * | 2022-10-21 | 2025-11-05 | リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド | Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用 |
| WO2024083256A1 (zh) | 2022-10-21 | 2024-04-25 | 上海领泰生物医药科技有限公司 | pan-KRAS降解剂及其制备方法和应用 |
| WO2024092420A1 (zh) * | 2022-10-31 | 2024-05-10 | 上海皓元医药股份有限公司 | 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法 |
| TW202430532A (zh) * | 2022-11-14 | 2024-08-01 | 美商安進公司 | 大環ｋｒａｓ抑制劑及使用方法 |
| CN121039137A (zh) | 2022-11-21 | 2025-11-28 | 树线生物科学公司 | 螺环二氢吡喃并嘧啶KRas抑制剂 |
| EP4626888A1 (en) | 2022-11-28 | 2025-10-08 | Redx Pharma Limited | Compounds |
| CN116554208A (zh) * | 2022-12-02 | 2023-08-08 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| WO2024123102A1 (ko) * | 2022-12-07 | 2024-06-13 | 에스케이바이오팜 주식회사 | Kras g12d 저해제로서 신규한 3환 화합물 및 이의 용도 |
| CN120322441A (zh) | 2022-12-20 | 2025-07-15 | 江苏恒瑞医药股份有限公司 | 一种kras g12d抑制剂的结晶形式及制备方法 |
| WO2024131827A1 (zh) | 2022-12-23 | 2024-06-27 | 上海和誉生物医药科技有限公司 | 一种kras g12d抑制剂及其应用 |
| CN115894503B (zh) * | 2022-12-30 | 2025-06-13 | 合肥诺全医药有限公司 | 一种氮杂环戊烷衍生物的制备方法 |
| WO2024158242A1 (ko) * | 2023-01-25 | 2024-08-02 | 주식회사 엔바이오스 | Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물 |
| TW202444727A (zh) | 2023-01-26 | 2024-11-16 | 美商艾維納斯手術有限公司 | 基於cereblon之kras降解protac及其相關用途 |
| WO2024179546A1 (en) * | 2023-03-01 | 2024-09-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| WO2024186680A1 (en) * | 2023-03-03 | 2024-09-12 | Frontier Medicines Corporation | Methods for preparing pyrrolizidine compounds |
| WO2024192424A1 (en) | 2023-03-15 | 2024-09-19 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| KR20250164300A (ko) | 2023-03-30 | 2025-11-24 | 일라이 릴리 앤드 캄파니 | KRas 억제제 |
| US20240368193A1 (en) | 2023-03-31 | 2024-11-07 | Eli Lilly And Company | Kras inhibitors |
| WO2024209717A1 (ja) | 2023-04-06 | 2024-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN118791506A (zh) | 2023-04-14 | 2024-10-18 | 广东东阳光药业股份有限公司 | Kras抑制剂化合物、其药物组合物及其用途 |
| AU2024273014A1 (en) * | 2023-05-12 | 2025-11-13 | Blossomhill Therapeutics, Inc. | Fused ring kras inhibitors for treating disease |
| WO2024236452A1 (en) | 2023-05-12 | 2024-11-21 | Jazz Pharmaceuticals Ireland Ltd. | Pyrazolo[4,3-f]quinazoline derivatives as modulators of g12d mutant kras useful for the treatment of cancer |
| WO2024238633A2 (en) * | 2023-05-15 | 2024-11-21 | Mirati Therapeutics, Inc. | Kras g12s and g12c inhibitors |
| WO2024243186A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as nras inhibitors |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| AR133027A1 (es) | 2023-06-22 | 2025-08-20 | Astellas Pharma Inc | Composición farmacéutica que comprende un compuesto de quinazolina |
| AR133028A1 (es) | 2023-06-22 | 2025-08-20 | Astellas Pharma Inc | Composición farmacéutica que comprende un degradador de todas las kras |
| WO2025011634A1 (zh) * | 2023-07-13 | 2025-01-16 | 上海森辉医药有限公司 | Kras g12d中间体的制备方法 |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025024447A2 (en) * | 2023-07-24 | 2025-01-30 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of mrtx1133 |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| WO2025040767A1 (en) | 2023-08-22 | 2025-02-27 | Sanofi | 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250101043A1 (en) | 2023-09-27 | 2025-03-27 | Eli Lilly And Company | Kras inhibitors |
| WO2025076044A1 (en) | 2023-10-03 | 2025-04-10 | PAQ Therapeutics Inc. | Kras proteolysis targeting chimeras |
| WO2025077663A1 (zh) * | 2023-10-08 | 2025-04-17 | 成都海博为药业有限公司 | 一种稠环化合物及应用 |
| WO2025080593A1 (en) | 2023-10-09 | 2025-04-17 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| WO2025077770A1 (zh) * | 2023-10-10 | 2025-04-17 | 成都海博为药业有限公司 | 一种稠环化合物及在kras抑制剂方面的应用 |
| WO2025080956A1 (en) | 2023-10-12 | 2025-04-17 | Mirati Therapeutics, Inc. | Mrtx1133 pharmaceutical compositions |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| WO2025107579A1 (zh) * | 2023-11-20 | 2025-05-30 | 贝达药业股份有限公司 | 一种靶向泛kras蛋白降解剂的化合物及其应用 |
| CN117683052A (zh) * | 2023-12-07 | 2024-03-12 | 上海相辉医药科技有限公司 | 一种kras g12d抑制剂mrtx1133的制备方法 |
| CN117756640B (zh) * | 2023-12-14 | 2025-09-26 | 江苏宝众宝达药业股份有限公司 | 一种两步升温法制备高纯度3,3'-二氨基联苯胺的方法 |
| WO2025136346A1 (en) * | 2023-12-19 | 2025-06-26 | Amgen Inc. | Indazole containing compounds and methods of use |
| KR102738924B1 (ko) * | 2023-12-26 | 2024-12-06 | 주식회사 베노바이오 | Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119684314A (zh) * | 2024-01-26 | 2025-03-25 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| WO2025163494A1 (en) | 2024-01-29 | 2025-08-07 | Jazz Pharmaceuticals Ireland Ltd. | Condensed azines for the treatment of cancer |
| WO2025170938A1 (en) * | 2024-02-06 | 2025-08-14 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| WO2025194057A1 (en) * | 2024-03-14 | 2025-09-18 | Amgen Inc. | Macrocyclic compounds as modulators of kras and uses thereof |
| WO2025194054A1 (en) * | 2024-03-14 | 2025-09-18 | Amgen Inc. | Spirocyclic compounds as modulators of kras and uses thereof |
| WO2025217015A1 (en) | 2024-04-08 | 2025-10-16 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer |
| WO2025231310A1 (en) | 2024-05-03 | 2025-11-06 | Mirati Therapeutics, Inc. | Crystalline forms of mrtx1133 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
Family Cites Families (207)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2241891T3 (es) | 2001-01-02 | 2005-11-01 | F. Hoffmann-La Roche Ag | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b. |
| US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US9562019B2 (en) | 2006-12-21 | 2017-02-07 | Sloan-Kettering Institute For Cancer Research | Substituted pyridazines as EGFR and/or KRAS inhibitors |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| KR20110046514A (ko) | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| WO2010124114A1 (en) | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| CA2785284A1 (en) | 2009-12-25 | 2011-06-30 | Tomoyuki Kamino | Novel aryl urea derivative |
| CN102812167A (zh) | 2009-12-30 | 2012-12-05 | 阿维拉制药公司 | 蛋白的配体-介导的共价修饰 |
| US20150087628A1 (en) | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| ES2683380T3 (es) * | 2012-06-08 | 2018-09-26 | Sensorion | Inhibidores del receptor H4 para tratar el tinnitus |
| WO2014011973A2 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-ras-selective lethal compounds and their use |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| AU2014239542A1 (en) | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| WO2015054572A1 (en) | 2013-10-10 | 2015-04-16 | Araxes Pharma Llc | Inhibitors of kras g12c |
| CA2950581A1 (en) | 2014-05-30 | 2015-12-03 | The Trustees Of Columbia University In The City Of New York | Multivalent ras binding compounds |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10421764B2 (en) | 2015-04-24 | 2019-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Mutant KRas inhibitors |
| US10857140B2 (en) | 2015-05-06 | 2020-12-08 | The Regents Of The University Of California | K-Ras modulators |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| TW201723176A (zh) | 2015-09-24 | 2017-07-01 | Ｉｏｎｉｓ製藥公司 | Ｋｒａｓ表現之調節劑 |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| WO2017070611A1 (en) | 2015-10-22 | 2017-04-27 | The Scripps Research Institute | Cysteine reactive probes and uses thereof |
| WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| WO2017079864A1 (en) | 2015-11-12 | 2017-05-18 | Hangzhou Yier Biotech Co., Ltd. | Treatment of cancers related to chronically active ras |
| TW201726656A (zh) | 2015-11-16 | 2017-08-01 | 亞瑞克西斯製藥公司 | 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US20170283445A1 (en) | 2016-04-05 | 2017-10-05 | University Of South Carolina | Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) * | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN110603254B (zh) | 2016-11-30 | 2024-04-12 | 班塔姆制药有限责任公司 | 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法 |
| JP2020513403A (ja) | 2016-11-30 | 2020-05-14 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法 |
| AU2017378487B2 (en) | 2016-12-15 | 2022-03-31 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| EP3878850A1 (en) | 2016-12-22 | 2021-09-15 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| EP3558955B1 (en) | 2016-12-22 | 2021-08-11 | Amgen Inc. | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| US10344026B2 (en) | 2017-01-18 | 2019-07-09 | Nantbio, Inc. | Compositions and methods of targeting mutant K-ras |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| EP3573966A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused n-heterocyclic compounds and methods of use thereof |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| EP3612526A2 (en) | 2017-04-20 | 2020-02-26 | The Regents of the University of California | K-ras modulators |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| WO2020027202A1 (ja) | 2018-07-31 | 2020-02-06 | 本田技研工業株式会社 | 電力予測システム、電力予測装置、電力予測方法、プログラム、及び記憶媒体 |
| CN109413550B (zh) | 2018-09-30 | 2021-03-09 | 华为技术有限公司 | 音频播放电路和终端 |
| CN111193490B (zh) | 2018-11-14 | 2025-05-13 | 天津大学 | 散热结构、带散热结构的体声波谐振器、滤波器和电子设备 |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| US20220193242A1 (en) | 2019-02-07 | 2022-06-23 | The Regents Of The University Of California | Immunophilin-dependent inhibitors and uses thereof |
| EP3924687A4 (en) | 2019-02-11 | 2022-11-02 | Mesomat Inc. | SENSING FIBERS FOR STRUCTURAL STRESS MONITORING |
| KR102747104B1 (ko) | 2019-02-18 | 2024-12-27 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| GB201902392D0 (en) | 2019-02-21 | 2019-04-10 | Cambridge Entpr Ltd | Modular binding proteins |
| US20220313700A1 (en) | 2019-02-26 | 2022-10-06 | Cell Response, Inc. | Methods for treating map3k8 positive cancers |
| WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| US12117170B2 (en) | 2019-03-05 | 2024-10-15 | Questor Technology Inc. | Gas incinerator system |
| EP3935060B1 (en) | 2019-03-05 | 2023-11-15 | Astrazeneca AB | Fused tricyclic compounds useful as anticancer agents |
| CA3131138A1 (en) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| US20220160714A1 (en) | 2019-03-22 | 2022-05-26 | Icahn School Of Medicine At Mount Sinai | Methods for treating colorectal cancer |
| EP3946338B1 (en) | 2019-03-29 | 2025-06-18 | Kura Oncology, Inc. | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
| WO2020205473A1 (en) | 2019-03-29 | 2020-10-08 | Decerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
| KR102222693B1 (ko) | 2019-04-04 | 2021-03-04 | 금정제약 주식회사 | H-rev107 유래 펩타이드의 신규한 용도 |
| US20220227740A1 (en) | 2019-04-15 | 2022-07-21 | Tosk, Inc. | Modulators of RAS GTPase |
| US20200335182A1 (en) | 2019-04-16 | 2020-10-22 | Uratim Ltd. | Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions |
| CN113767106B (zh) | 2019-04-28 | 2024-02-20 | 劲方医药科技(上海)有限公司 | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| PL3966206T3 (pl) | 2019-05-10 | 2024-01-29 | Deciphera Pharmaceuticals, Llc | Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| AU2020279253A1 (en) | 2019-05-20 | 2021-12-16 | 1200 Pharma Llc | KRAS G12C inhibitors and uses thereof |
| PH12021552922A1 (en) | 2019-05-21 | 2022-04-04 | Amgen Inc | Solid state forms |
| KR20220010542A (ko) | 2019-05-21 | 2022-01-25 | 인벤티스바이오 컴퍼니 리미티드 | 헤테로 고리 화합물, 이의 제조 방법 및 용도 |
| US12252486B2 (en) | 2019-05-21 | 2025-03-18 | Amgen Inc. | Solid state forms |
| EP3972963A1 (en) | 2019-05-21 | 2022-03-30 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| WO2020247914A1 (en) | 2019-06-07 | 2020-12-10 | Emory University | Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto |
| WO2020252336A1 (en) | 2019-06-12 | 2020-12-17 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| CN114222729A (zh) | 2019-06-12 | 2022-03-22 | 范德比尔特大学 | 氨基酸转运抑制剂及其用途 |
| CN114040914B (zh) | 2019-07-01 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| MX2022001421A (es) | 2019-08-02 | 2022-06-08 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto tetracíclico, método de preparación y uso del mismo. |
| TWI752580B (zh) | 2019-08-07 | 2022-01-11 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
| CN114174298B (zh) | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| CN112390797A (zh) | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
| WO2021031952A1 (zh) | 2019-08-16 | 2021-02-25 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 |
| AU2020334069A1 (en) | 2019-08-22 | 2022-03-24 | The Regents Of The University Of Michigan | Method of treating KRAS-associated cancers |
| WO2021037018A1 (zh) | 2019-08-26 | 2021-03-04 | 南京创济生物医药有限公司 | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 |
| KR20220071193A (ko) | 2019-08-29 | 2022-05-31 | 미라티 테라퓨틱스, 인크. | Kras g12d 억제제 |
| WO2021043322A1 (zh) | 2019-09-06 | 2021-03-11 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| EP3819300A4 (en) | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
| US20220331401A1 (en) | 2019-09-10 | 2022-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating kras mutant cancers |
| WO2021051034A1 (en) | 2019-09-13 | 2021-03-18 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| EP4031542B1 (en) | 2019-09-18 | 2025-10-15 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12c mutant |
| EP4043464A4 (en) | 2019-09-20 | 2023-10-04 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | FUSED PYRIDONE COMPOUND, PREPARATION METHOD AND USE THEREOF |
| WO2021061515A1 (en) | 2019-09-23 | 2021-04-01 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| US20210094919A1 (en) | 2019-09-25 | 2021-04-01 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| WO2021058018A1 (en) | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Inhibitors of kras g12c |
| WO2021063346A1 (zh) | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
| WO2021068898A1 (zh) | 2019-10-10 | 2021-04-15 | 信达生物制药(苏州)有限公司 | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 |
| JP6754125B1 (ja) | 2019-10-15 | 2020-09-09 | 学校法人東京理科大学 | Ｂｒａｐ２作用増強剤 |
| EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021080359A1 (ko) | 2019-10-23 | 2021-04-29 | 에스케이바이오팜 주식회사 | 바이사이클릭 화합물 및 이의 용도 |
| CN112694475B (zh) | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| AU2020369569A1 (en) | 2019-10-24 | 2022-04-14 | Amgen Inc. | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| US12054497B2 (en) | 2019-10-30 | 2024-08-06 | Genfleet Therapeutics (Shanghai)Inc. | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| CN119424423A (zh) | 2019-10-31 | 2025-02-14 | 大鹏药品工业株式会社 | 4-氨基丁-2-烯酰胺衍生物及其盐 |
| WO2021084765A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd | 4-aminobut-2-enamide derivatives and salts thereof |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN113286794B (zh) | 2019-11-04 | 2024-03-12 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
| CN112778301A (zh) | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| WO2021093758A1 (zh) | 2019-11-15 | 2021-05-20 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021104431A1 (zh) | 2019-11-29 | 2021-06-03 | 苏州信诺维医药科技股份有限公司 | Kras g12c抑制剂化合物及其用途 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| EP4015520B1 (en) | 2019-12-02 | 2025-02-19 | 280 Bio, Inc. | Oxygen-containing heterocyclic compound, preparation method and application thereof |
| WO2021113595A1 (en) | 2019-12-06 | 2021-06-10 | Beta Pharma, Inc. | Phosphorus derivatives as kras inhibitors |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| US12365706B2 (en) | 2019-12-18 | 2025-07-22 | Merck Sharp & Dohme Llc | Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant |
| CN114349750A (zh) | 2019-12-19 | 2022-04-15 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| WO2021121397A1 (zh) | 2019-12-19 | 2021-06-24 | 首药控股(北京)股份有限公司 | 取代的炔基杂环化合物 |
| US20230062486A1 (en) | 2019-12-19 | 2023-03-02 | Betta Pharmaceuticals Co., Ltd | Kras g12c inhibitor and pharmaceutical use thereof |
| TR201920922A2 (tr) | 2019-12-20 | 2020-06-22 | Ankara Ueniversitesi | 3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler |
| EP4076667A1 (en) | 2019-12-20 | 2022-10-26 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US12479843B2 (en) | 2019-12-27 | 2025-11-25 | Soochow University | Spiro ring-containing quinazoline compounds |
| CN113045565A (zh) | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| WO2021139678A1 (zh) | 2020-01-07 | 2021-07-15 | 广州百霆医药科技有限公司 | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 |
| CN113087700B (zh) | 2020-01-08 | 2023-03-14 | 苏州亚盛药业有限公司 | 螺环四氢喹唑啉 |
| CA3163216A1 (en) | 2020-01-10 | 2021-07-15 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| WO2021143693A1 (zh) | 2020-01-13 | 2021-07-22 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| KR102396930B1 (ko) | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| KR102382613B1 (ko) | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| WO2021147967A1 (zh) | 2020-01-21 | 2021-07-29 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| US20230099858A1 (en) | 2020-02-20 | 2023-03-30 | Beta Pharma, Inc. | Pyridopyrimidine derivatives as kras inhibitors |
| TW202140450A (zh) | 2020-02-24 | 2021-11-01 | 大陸商泰勵生物科技（上海）有限公司 | 用於癌症治療的ｋｒａｓ抑制劑 |
| EP4112606A4 (en) | 2020-02-24 | 2024-04-10 | Shanghai Zheye Biotechnology Co., Ltd. | AROMATIC COMPOUND AND ITS USE IN THE PREPARATION OF ANTINEOPLASIC DRUGS |
| WO2021173923A1 (en) | 2020-02-28 | 2021-09-02 | Erasca, Inc. | Pyrrolidine-fused heterocycles |
| WO2021175199A1 (zh) | 2020-03-02 | 2021-09-10 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
| EP4115887A4 (en) | 2020-03-03 | 2024-07-17 | Wellmarker Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER HAVING KRAS MUTATION AND RON ACTIVATION |
| CA3174538A1 (en) | 2020-03-05 | 2021-09-10 | The Regents Of The Universtiy Of Michigan | Inhibitors of egfr, kras, braf, and other targets and use of the same |
| AU2021230372A1 (en) | 2020-03-05 | 2022-09-22 | The Regents Of The University Of Michigan | Inhibitors of EGFR, KRAS, BRAF, and other targets and use of the same |
| CN117510492A (zh) | 2020-03-12 | 2024-02-06 | 德昇济医药(无锡)有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2021185233A1 (en) | 2020-03-17 | 2021-09-23 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| CN115335379B (zh) | 2020-03-25 | 2024-03-29 | 微境生物医药科技(上海)有限公司 | 含螺环的喹唑啉化合物 |
| KR20220164015A (ko) | 2020-04-03 | 2022-12-12 | 메드샤인 디스커버리 아이엔씨. | 옥타하이드로피라지노디아자나프티리딘 디온 화합물 |
| WO2021207172A1 (en) | 2020-04-06 | 2021-10-14 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| CN115244058A (zh) | 2020-04-08 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 |
| EP4135844A1 (en) | 2020-04-16 | 2023-02-22 | Incyte Corporation | Fused tricyclic kras inhibitors |
| WO2021216770A1 (en) | 2020-04-22 | 2021-10-28 | Accutar Biotechnology Inc. | Substituted tetrahydroquinazoline compounds as kras inhibitors |
| WO2021217019A1 (en) | 2020-04-23 | 2021-10-28 | The Regents Of The University Of California | Ras inhibitors and uses thereof |
| US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US20230174526A1 (en) | 2020-04-29 | 2023-06-08 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| WO2021219090A1 (zh) | 2020-04-29 | 2021-11-04 | 北京泰德制药股份有限公司 | 喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂 |
| TW202144349A (zh) | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN113666923A (zh) | 2020-05-15 | 2021-11-19 | 苏州泽璟生物制药股份有限公司 | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 |
| WO2021236475A1 (en) | 2020-05-18 | 2021-11-25 | Asinex Corporation | Compounds that inhibit asparagine synthetase and their methods of use |
| TWI799871B (zh) | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| CA3180314A1 (en) | 2020-05-29 | 2021-12-02 | John Graeme HODGSON | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 |
| KR20230019462A (ko) | 2020-06-02 | 2023-02-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
| US20230202981A1 (en) | 2020-06-04 | 2023-06-29 | Baskaran Pillai | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
| IL298670A (en) | 2020-06-04 | 2023-01-01 | Antengene Discovery Ltd | Inhibitors of kras g12c protein and uses thereof |
| WO2021248083A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| US20230026856A1 (en) | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248082A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248079A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| US20230023009A1 (en) | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021252339A1 (en) | 2020-06-08 | 2021-12-16 | Accutar Biotechnology, Inc. | Substituted purine-2,6-dione compounds as kras inhibitors |
| WO2021249563A1 (zh) | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| WO2021257828A1 (en) | 2020-06-18 | 2021-12-23 | Shy Therapeutics, Llc | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2021259331A1 (zh) | 2020-06-24 | 2021-12-30 | 南京明德新药研发有限公司 | 八元含n杂环类化合物 |
| CN115836055A (zh) | 2020-06-30 | 2023-03-21 | 益方生物科技(上海)股份有限公司 | 喹唑啉化合物、其制备方法和用途 |
| US20230279025A1 (en) | 2020-07-16 | 2023-09-07 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| TW202214608A (zh) | 2020-07-20 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 |
| CN115052870B (zh) | 2020-08-02 | 2024-02-20 | 上海喆邺生物科技有限公司 | 一种芳香类化合物及其在抗肿瘤药物中的应用 |
| WO2022031678A1 (en) | 2020-08-04 | 2022-02-10 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US20230322788A1 (en) | 2020-08-05 | 2023-10-12 | Beigene, Ltd. | Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors |
| US20230303551A1 (en) | 2020-08-13 | 2023-09-28 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
-
2020
- 2020-08-27 KR KR1020227009947A patent/KR20220071193A/ko active Pending
- 2020-08-27 EP EP20859068.7A patent/EP4021444A4/en active Pending
- 2020-08-27 CN CN202080076261.5A patent/CN114615981B/zh active Active
- 2020-08-27 CA CA3148745A patent/CA3148745A1/en active Pending
- 2020-08-27 MX MX2022002465A patent/MX2022002465A/es unknown
- 2020-08-27 PH PH1/2022/550469A patent/PH12022550469A1/en unknown
- 2020-08-27 WO PCT/US2020/048194 patent/WO2021041671A1/en not_active Ceased
- 2020-08-27 BR BR112022003543A patent/BR112022003543A2/pt unknown
- 2020-08-27 JP JP2022513171A patent/JP7622043B2/ja active Active
- 2020-08-27 US US17/005,004 patent/US11453683B1/en active Active
- 2020-08-27 AU AU2020337938A patent/AU2020337938B2/en active Active
- 2020-08-28 TW TW114103629A patent/TW202523663A/zh unknown
- 2020-08-28 TW TW109129561A patent/TWI874443B/zh active
-
2022
- 2022-02-23 CL CL2022000447A patent/CL2022000447A1/es unknown
- 2022-02-23 IL IL290845A patent/IL290845A/en unknown
- 2022-02-24 ZA ZA2022/02362A patent/ZA202202362B/en unknown
- 2022-03-29 CO CONC2022/0003782A patent/CO2022003782A2/es unknown
- 2022-07-20 US US17/869,575 patent/US11964989B2/en active Active
-
2024
- 2024-04-23 US US18/644,056 patent/US20240309020A1/en active Pending
-
2025
- 2025-01-14 JP JP2025004802A patent/JP2025063176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025063176A5 (enExample) | ||
| JP2024023189A5 (enExample) | ||
| KR100258668B1 (ko) | 2'-할로메틸리덴 유도체와 s-기 또는 m-기 특이성 항종양제를 포함하는 암치료용 조성물 | |
| RU2011142750A (ru) | Способ лечения путем применения комбинированной терапии | |
| JP2011529474A (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2008536807A5 (enExample) | ||
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| EA003134B1 (ru) | Противоопухолевая композиция, содержащая синергическую комбинацию производного антрациклина и производного камптотецина | |
| JP2020512977A5 (enExample) | ||
| KR102708246B1 (ko) | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 | |
| JPWO2020163823A5 (enExample) | ||
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| WO2023165603A1 (en) | Dna-pk inhibitor and combination use thereof | |
| FI2968346T3 (fi) | Menetelmiä ja koostumuksia gamma-glutamyylisyklin muokkaamiseksi | |
| JP2003523326A (ja) | トポイソメラーゼｉ阻害を有する１０，１１−ジフルオロメチレンジオキシカンプトテシン化合物 | |
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| JP2019519563A5 (enExample) | ||
| KR100853955B1 (ko) | 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물 | |
| CN110573620B (zh) | 血癌治疗剂 | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| KR20250044686A (ko) | G12d 돌연변이체 kras 억제 활성을 갖는 이관능성 화합물을 포함하는 항암제의 조합물 | |
| EP4506015A1 (en) | Combination of a mps1 inhibitor and an antibody drug conjugate | |
| JP2008546777A5 (enExample) | ||
| US20240173323A1 (en) | Combination therapy for cancer treatment | |
| WO2010131460A1 (ja) | テガフール・ギメラシル・オテラシルカリウム配合剤及びオキサリプラチンを含有する抗腫瘍剤 |